Director, Market Access,Switzerland

Das ist der Job

The company’s RD pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

Darum lohnt es sich

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. /p h3The Opportunity /h3 pThe Market Access Director, Switzerland is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies.

This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities. /p pThis position will partner with regulatory, commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence‑based HTA, Pricing Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches aligned with patient needs. /p h3Required Skills, Experience and Education /h3 ul liLead Market Access Reimbursement: Develop and implement strategies to support access and pricing decisions for RevMed portfolio and launches within the Switzerland healthcare system. /li liHTA Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments and pricing negotiations with statutory health insurance decision makers. /li liPartner with regional and local Medical Affairs and Marketing team to translate clinical and economic evidence into compelling value communications tailored for Switzerland payers. /li liBuild and maintain strong relationships with key external stakeholders (payers, HTA authorities, policy influencers).

Representation of Revolution Medicines at local trade associations for market access subjects. /li liWork with Midsized Markets and Regional Market Access teams to align local access strategy with broader European and corporate objectives, especially in terms of aligning the European regulatory strategy and execution with local value dossier submission and pricing negotiation strategy. /li liProvide early market access input to regional and European clinical development and medical teams. /li liLead negotiation with all levels of national payers. /li liDevelop innovative pricing and value based contracting models to optimize the acceleration of reimbursement approvals. /li liPolicy Monitoring: Monitor health policy developments, HTA processes and local reimbursement environments to inform strategy. /li liRepresent Market Access in Switzerland Leadership Team meetings and contribute to overall business strategy. /li liDrive access and value related projects such as landscape assessments, payer market research, payer advisory boards and general guidance on local strategies. /li liDevelopment of outreach and engagement plan for key payers creating and maintaining a strong network. /li liEarly access planning of new products and indications, drive launch readiness for multiple oncology assets (portfolio responsibility). /li liInfluence European and Midsised Markets access strategy based on local payer insights from a leadership position. /li liTravel nationally and internationally. /li /ul h3Preferred Skills /h3 ul liAdvanced degree (e.g., Life Sciences, Pharmacy, Health Economics, Public Health). /li liA minimum of 10 years’ experience in market access, pricing, reimbursement or health economics (pharma/biotech) in Switzerland. /li liProven value and benefit assessment experience, with deep understanding of Switzerland payer decision‑making. /li liDemonstrated success and experience supporting oncology product pre‑launch, launch and post launch in Switzerland. /li liDemonstrated success in negotiating pricing and reimbursement conditions with public administrations and health authorities. /li liStrong stakeholder management and ability to collaborate with internal and external partners. /li liExcellent interpersonal and communication skills. /li liScientific and solution‑orientated mindset and capability to move and execute in a rapidly changing, ambiguous environment. /li liStrong understanding of local healthcare systems, customer dynamics, and reimbursement environments. /li liExperience in a biotech and/or in a build‑out. /li liHigh capacity of social competence for teamwork, coaching and situational leadership. /li /ul /p ppRevolution Medicines is a late‑stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers.

The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.